Drug Approval | January 17, 2022
Glenmark Pharmaceuticals receives ANDA tentative approval for Regadenoson injection
The company has 47 ANDA's pending approval with the U.S.FDA
The company has 47 ANDA's pending approval with the U.S.FDA
The recommended daily dose for Ryaltris is 2 sprays in each nostril twice daily
Ichnos will receive an upfront payment of Euro 20.8 million as well as additional development and commercial milestone payments and tiered royalties based upon future global sales
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
Ryaltris is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis
Clindamycin Phosphate Foam, 1% is the generic version of Evoclin Foam, 1%
These were the findings of the Post Marketing Surveillance (PMS), study of Favipiravir (FabiFlu) on over 1000 patients
The company reports revenue growth of 26% and PAT growth of 21% YoY
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
Subscribe To Our Newsletter & Stay Updated
